Vanda Pharmaceuticals, Inc. (VNDA)

[surf1944]

7:57AM Vanda Pharma presents new data at SLEEP 2012 Annual Meeting: 70% of totally blind individuals with sleep complaints suffer from chronic circadian rhythm sleep disorder (VNDA) 4.23 : Co announced that data presented at SLEEP, the 26th annual meeting of the Associated Professional Sleep Societies, show that 70% of totally blind people with sleep complaints suffer from Non-24-Hour Disorder (Non-24). Non-24 is a circadian rhythm disorder characterized by a chronically misaligned body clock. There are currently no FDA approved medications for the treatment of Non-24. Of the 143 totally blind subjects with sleep complaints in the study, 70% were found to not be entrained to a 24-hour day and, as a result, diagnosed with Non-24. Circadian period in Non-24 patients ranged from 24.08 to 25.34, with a median tau of 24.45, meaning study subject's internal clocks delay a median of 27 minutes every day. The effect is cumulative, putting subjects to sleep later and later each day until they cycle around the clock and begin again.Vanda is currently studying the efficacy of tasimelteon in Non-24 in two multi-national Phase III studies, SET and RESET, which are ongoing and expected to be completed by the end of 2012.